05.12.21 How Is The Shift To Decentralized Trials Impacting Clinical Sites?
Sponsor
Is clinical development prepared for the paradigm shift caused by COVID-19? The pandemic has forced the industry to reevaluate how to engage with patients and acquire patient data without direct, in-person access. Biopharmaceutical companies, medical device companies, and CROs from around the world were surveyed to explore the impact on clinical trials in this new paradigm and gain insights into their experiences operationalizing trials in a pandemic. Learn more.
Featured Editorial
By Ed Miseta, Chief Editor, Clinical Leader
The emergence of the COVID pandemic in 2019 hit a lot of organizations in the R&D and clinical space by surprise. The companies and organizations that convene stakeholders were no exception. One of those organizations was DIA. When shutdowns began to sweep across the globe in March, DIA’s Global Annual Meeting, which brings together t
01.25.21 Research Report Shows Phase II/III Spending Will Increase
Continuing our Cell & Gene Series,
Business of Biotech features Dr. Bobby Gaspar, Orchard Therapeutics CEO, speaking on the challenges his company faces in the production of hematopoietic stem cells to treat neurometabolic disorders, primary immune deficiencies, and blood disorders. Listen now and subscribe so you never miss an episode.
Featured Editorial
Research firm Industry Standard Research recently published its
Phase II/III Study Trends and Market Outlook report. The goal of this report is to provide readers with a high-level view of the Phase 2 and 3 clinical development space to illustrate current market dynamics and inform strategic planning.